)
Visual
test
AcuCort
AcuCort (ACUC) investor relations material
AcuCort Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary14 Nov, 2025
Executive summary
Revenue for Q3 2025 was 517 tkr, down from 675 tkr in Q3 2024; net loss after tax widened to -5,340 tkr from -2,484 tkr year-over-year.
For the nine months ending September 2025, revenue was 679 tkr (675 tkr in 2024), with a net loss after tax of -19,433 tkr compared to -9,900 tkr year-over-year.
ZeqmelitⓇ sales began in Denmark; SME status extended by EMA; new Business Development Director recruited.
Strategic focus on international expansion, with ongoing negotiations for distribution in the Middle East, Gulf States, and several European countries.
U.S. market entry progressing, with FDA discussions ongoing and trademark registration completed.
Financial highlights
Q3 2025 revenue: 517 tkr (Q3 2024: 675 tkr); nine-month revenue: 679 tkr (2024: 675 tkr).
Q3 2025 net loss after tax: -5,340 tkr (Q3 2024: -2,484 tkr); nine-month net loss: -19,433 tkr (2024: -9,900 tkr).
Cash position at period end: 34,076 tkr.
Operating expenses increased due to commercialization and regulatory activities.
1,852 tkr in development costs capitalized in Q3, mainly for regulatory and production work.
Outlook and guidance
Anticipates further regulatory approvals outside the Nordics, with sales expected to rise as ZeqmelitⓇ becomes more established.
Expansion planned into additional European countries and the U.S., expected to generate new revenue streams.
Available liquidity, recent capital raise, and sales are expected to cover working capital needs for the next 12 months.
Timeline for US market approval?
Status of definitive agreements with partners?
When does Nordic sales growth accelerate?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 032640
Net profit rose 61.9% on strong mobile and enterprise growth, with AIDC and AI driving expansion. - S68
Record revenue, robust margins, and strong IPO pipeline highlight broad-based growth. - 6417
Strong pachinko sales drove revenue growth, with major treasury stock cancellation planned. - 6723
AI and industrial demand drive growth; timing business sold for $3B; inventory targets raised. - BPT
H1 FY26 revenue hit $1B, with strong gas prices and LNG cargoes offsetting lower production. - CPAY
Record 2025 results and 2026 outlook driven by strong segment growth and capital deployment. - LOT
A$76M equity raise supports Kayelekera ramp-up and Letlhakane development amid strong uranium demand. - SYM
Revenue up 29% to $630M, net income $13.36M, $22.3B backlog, strong cash, legal risks persist. - TENB
Record 2025 results with double-digit growth, strong cash flow, and expanding AI-driven platform. - DHX
Q4 2025 revenue down 10% YoY; FY 2026 guidance targets $118M–$122M revenue.
Next AcuCort earnings date
Q4 202521 Feb, 2026
AcuCort
Next AcuCort earnings date
Q4 202521 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
AcuCort is a biotechnology company that develops smart medicines for the treatment of chronic diseases, with a focus on pain. Their mission is to identify, develop and commercialize innovative products that meet the patient’s need for convenient and effective treatment.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage